Eosinophilic Esophagitis
Eosinophilic Esophagitis Market

Eosinophilic Esophagitis (EoE) is a chronic immune system disease in which a type of white blood cell (eosinophil) builds up in the lining of the tube that connects your mouth to your stomach (esophagus).


Eosinophilic Esophagitis is characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation.


Eosinophilic Esophagitis Epidemiological Segmentation 


The Epidemiological Segmentation of Eosinophilic Esophagitis in 7MM from 2018 to 2030 is segmented into:-


  • Diagnosed prevalence cases of Eosinophilic Esophagitis
  • Gender-specific cases of Eosinophilic Esophagitis
  • Age-specific cases of Eosinophilic Esophagitis


Eosinophilic Esophagitis Epidemiological Insights Observed in 2020


  • The total diagnosed prevalent cases of Eosinophilic Esophagitis were estimated to be 547,924 in 2020.
  • The prevalent Eosinophilic Esophagitis cases in the United States accounted for 58% of the total cases of Eosinophilic Esophagitis.
  • The diagnosed population of Eosinophilic Esophagitis in France was 33,450
  • The diagnosed population of Eosinophilic Esophagitis in Germany was observed to be 39,531
  • The diagnosed population of Eosinophilic Esophagitis in Spain was 24,612 
  • In the United States, the Gender-Specific cases of Eosinophilic Esophagitis in males were found to be 207,629, whereas, in females, it was observed to be 111,800.


Eosinophilic Esophagitis Market


The market size of Eosinophilic Esophagitis in the 7MM was found to be USD 430.9 million in 2020. 


Eosinophilic Esophagitis Market Drivers


  • Increasing awareness
  • The emergence of non-invasive modalities
  • Identification of biomarkers
  • Development of animal models


Eosinophilic Esophagitis Market Barriers


  • High cost of treatment
  • Lack of multidisciplinary management
  • Lack of optimal endpoint for treatment

 

Eosinophilic Esophagitis Emerging Drugs

 

The emerging drugs of the Eosinophilic Esophagitis market are


  • Budesonide Oral Suspension
  • Dupilumab
  • Cendakimab
  • APT-1011
  • Benralizumab
  • Lirentelimab, and others


Eosinophilic Esophagitis Key Players


The key players working in the Eosinophilic Esophagitis market are

  • Takeda
  • Regeneron Pharmaceuticals
  • Sanofi
  • Bristol-Myers Squibb
  • Ellodi Pharmaceuticals
  • AstraZeneca
  • Allakos, and others